This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
FibroGen secured regulatory approvals for roxadustat in China and Europe, but the FDA rejected the drug and asked for another clinical trial. By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially resuming development of roxadustat in another indication. The post AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal appeared first on MedCity News.
A year after Impetus Digital first calculated and offset all of our home office-related emissions , we’re excited to announce that we have now implemented Phase 2 of our journey toward carbon neutrality. As of January 2024, all of the carbon emissions associated with Impetus Digital staff attending hybrid meetings live (i.e., flights, ground transportation for local meetings, and accommodation) have beenand will continue to beoffset.
Improving the identification and validation of disease-specific drug targets in a cell-type and patient-specific manner early on will not only reduce the failure rate and cost that is so inherent in current drug development processes but also allow the development of more effective precision medicines, improving patient outcomes. The post The Future of Drug Discovery is 3D appeared first on MedCity News.
When the pandemic forced teams to shift away from in-person meetings, pharmaceutical sales training leaders had to rethink how they prepared reps for conversations with healthcare professionals. Virtual and hybrid learning models, once considered secondary to live training, quickly became essential. Now, even as in-person meetings return, companies find that a mix of formats works best.
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
Millies Series A round was co-led by TMV and Foreground Capital. The financing will help the company expand its offerings and footprint. The post Millie Raises $12M to Advance Maternal Healthcare appeared first on MedCity News.
Chronic Lymphocytic Leukemia (CLL) presents a complex treatment landscape. While advancements have led to new therapies, optimizing patient outcomes requires precise targeting of both healthcare providers (HCPs) and patients. Lab data, unlike claims data which offers a retrospective and often incomplete view of the patient journey, provides a real-time, granular snapshot of a patient's disease status, making it an indispensable tool for commercial pharma teams seeking to navigate this complexity
Chronic Lymphocytic Leukemia (CLL) presents a complex treatment landscape. While advancements have led to new therapies, optimizing patient outcomes requires precise targeting of both healthcare providers (HCPs) and patients. Lab data, unlike claims data which offers a retrospective and often incomplete view of the patient journey, provides a real-time, granular snapshot of a patient's disease status, making it an indispensable tool for commercial pharma teams seeking to navigate this complexity
[Sponsored] A webinar sponsored by Elation Health will offer insights and share tips on helping practices run more efficiently. It’s scheduled for Wednesday, February 26 at 3 pm ET. The post How Can Healthcare Practices Cut Waste? appeared first on MedCity News.
February 20, 2025 Danvers, Mass. CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host a virtual town hall on Bridging Innovation and Integrity: A Discussion of Responsible AI Practices via LinkedIn Live on Thursday, 27 February, 10:00 am EST/4:00 pm CET. Oliver Patel , AI Governance Lead at AstraZeneca , and Roanie Levy , former CEO and President of Access Copyright , will discuss building a responsible and ethical AI governance program, navigating
Panelists discuss how pharmacists play a crucial role in optimizing health outcomes for women with complex health needs through comprehensive medication management, personalized consultations, and interdisciplinary collaboration. They provide targeted medication therapy, monitor drug interactions, offer medication counseling, manage chronic conditions, support reproductive health, and help patients navigate complex treatment regimens with expertise and compassionate care.
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
The post AI Rights Reservation: Human Readable is Machine Readable An Interview with Haralambos (Babis) Marmanis appeared first on Copyright Clearance Center.
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
In this episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, discuss the implications of FDAs new draft guidance on complying with 21 CFR 211.110.
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
Panelists discuss how menopause represents a complex physiological transition characterized by hormonal fluctuations, reproductive system changes, and multifaceted symptoms affecting physical, psychological, and metabolic health. Comprehensive patient education, personalized management strategies, and holistic support are crucial for navigating this transformative life stage.
Semaglutide has been approved for reducing kidney disease progression and cardiovascular risk in patients with type 2 diabetes, marking a significant advancement in CKD management.
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights to commercialize the treatment outside of North America.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
175 
Let's personalize your content